ResearcherHarbin Medical UniversityNo recent work listed
Yang Yao
Matched on ORCID iD 0000-0003-2122-0136; OpenAlex author ID A5102008194. Sources: OpenAlex.
Their work
- Papers
- 2
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 7
2021: 1 paper · 2022: 1 paper
Papers 2
- HOXB9 blocks cell cycle progression to inhibit pancreatic cancer cell proliferation through the DNMT1/RBL2/c-Myc axis. Co-author DOI 10.1016/j.canlet.2022.215595↗
- Systemic Inflammatory Biomarkers, Especially Fibrinogen to Albumin Ratio, Predict Prognosis in Patients with Pancreatic Cancer. Co-author DOI 10.4143/crt.2020.330↗
Closest collaborators
The 7 strongest of 7 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Lin Fang · 2 shared papers, 2021–2022 · strength 0.24
- Paper HOXB9 blocks cell cycle progression to inhibit pancreatic cancer cell proliferation through the DNMT1/RBL2/c-Myc axis. DOI 10.1016/j.canlet.2022.215595↗
- Paper Systemic Inflammatory Biomarkers, Especially Fibrinogen to Albumin Ratio, Predict Prognosis in Patients with Pancreatic… DOI 10.4143/crt.2020.330↗
- Changjie Lou · 2 shared papers, 2021–2022 · strength 0.24
- Paper HOXB9 blocks cell cycle progression to inhibit pancreatic cancer cell proliferation through the DNMT1/RBL2/c-Myc axis. DOI 10.1016/j.canlet.2022.215595↗
- Paper Systemic Inflammatory Biomarkers, Especially Fibrinogen to Albumin Ratio, Predict Prognosis in Patients with Pancreatic… DOI 10.4143/crt.2020.330↗
- Yanqiao Zhang · 2 shared papers, 2021–2022 · strength 0.24
- Paper HOXB9 blocks cell cycle progression to inhibit pancreatic cancer cell proliferation through the DNMT1/RBL2/c-Myc axis. DOI 10.1016/j.canlet.2022.215595↗
- Paper Systemic Inflammatory Biomarkers, Especially Fibrinogen to Albumin Ratio, Predict Prognosis in Patients with Pancreatic… DOI 10.4143/crt.2020.330↗
- Hengzhen Li · 1 shared paper, 2022 · strength 0.13
- Dan Wang · 1 shared paper, 2021 · strength 0.11
- Zhiwei Li · 1 shared paper, 2021 · strength 0.11
- Jie Lian · 1 shared paper, 2021 · strength 0.11
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.